Dear Shareholders,
Previous President of India, Late Dr. APJ Abdul Kalam regularly used to quote "You are never given a fantasy without the ability to make it work out".
Dispatch of our ''focal point of incredibleness ''at Pune is reminiscent of our old affectionate recollections with Dr. Kalam. As we recall that him, we draw gigantic feeling of motivation and also desire. Motivation to remain against multifaceted difficulties as they rise and yearning to be an impactful pioneer in our part, while conquering all hindrances.
Much sooner, Bilcare set up its worldwide foot shaped impressions in the created economy, it had a dream to be worldwide pioneer, and in doing as such, it sought after a fantasy that encapsulates Dr. Kalam's' thought.
In numerous event, I had the chance to look for his instruct and favors wealth source with respect to inspiration, which thusly offered us in taking forward some of our development on medication some assistance with dispensing and ncID™ Technology.
Bilcare dependably took a gander at pharma bundling from an investigative, research point, which not just offered us to be a pioneer in a few medication some assistance with dispensing advances additionally secured these developments with worldwide licenses, which thusly helped us to be on top of things, while making our blessing from heaven!
Bilcare Research AG (BRAG), containing pharma, claim to fame and card bundling business in the US, Europe and now Asia, which constitute more than 80 % of Company's' aggregate income is ''Gaining Momentum'' to develop as key development driver for the Company, exhibiting solid turnover development and edge change in the ebb and flow year. Gloat's' Revenue has expanded from EUR 240 Mn. in (2011/12) to EUR 265 Mn. in (2014/15), current year, regardless of way out from bundling business worth EUR 40 Mn. Correspondingly, BRAG EBIDTA is up from EUR 8 Mn. in (2011/12) to EUR 27 Mn. in (2014/15) because of judicious technique execution, cost proficiency and realignment of business and items.
Boast business having merged and collected authority position in the US and Europe, is presently hoping to grow and tap high potential Asian markets. Bilcare Research AG procured Bilcare Singapore pharma bundling resources and adjusted to its European and US plan of action as a characteristic strategy, furthermore to grow its client base in Mainland China, and other Asian markets, making Singapore as an Asian Hub.
It is likewise conceivable to say that BRAG, a quickly leading so as to develop business is very much financed European saves money with stable reimbursement giving further driving force for development in deals and edges.
As a major aspect of limit development plan to mix development and meet client prerequisite, BRAG is presently contributing 15 Million Euro at its assembling site Staufen, Germany, where Bilcare is been referred to for quite a long time as a solid and submitted accomplice in the therapist movies market.
Our most recent two years abroad rebuilding exercise has launch to obvious result this year and this pattern should proceed in the following years.
Bilcare keeps on contributing on R&D exercises and viably use its speculations made on formation of examination locales bringing about effective expansion of more up to date items, forms administrations and advances to its development portfolio. Amid the budgetary year, Bilcare documented 2 new Patent applications identified with its inventive items and advances and were allowed 9 Patents, before connected.
Bilcare R&D got leap forward in growing light weight material that can have a great obstruction for ''Nuclear Radiation''. DRDO have taken their first model trial with this material and have put in a request for the same.
Bilcare GCS timed 12.8% Revenue development with expansion of 14 new customers. ''Comparator Sourcing'' business expanded generously over a year ago, indicating 40% development. With development and expanding client necessity from the west, GCS opened showcasing workplaces in USA and UK to catch future open door. We anticipate that this business division will cross INR 100 Cr. by one year from now.
Bilcare Technology made advances in stowing pharma and Government clients and critical pilot ventures. Discussing pharma, there was line incorporation venture for serialization administrations for essential, optional and tertiary level bundling for Biocon, including supply of auxiliary and tertiary marks. Additionally, we could execute serialization and track and follow according to DGFT and MoHFW command for optional and tertiary packs for Merck at Fulford India Ltd and Organ on India.
An outlook change in Bilcare ncID Technology is relied upon to be unleashed with incitement of exceptionally capable technocrat; who alongside his ''new group'' is chipping away at go-to-the-business sector technique with client arranged arrangement offerings.
Financials:
Absolute Standalone Revenue for the year declined from INR 394.47 Cr. in (FY14) to INR 335.60 Cr. in (FY15).
This loss of offers is basically by virtue of mash in working capital combined with misfortune/unfulfillment of requests, or as it were we needed to swear off requests close by because of crude material inaccessibility for said reasons. This brought about diminished EBIDTA of INR 25.29 Cr. in the present year, (FY15) from INR 57.49 Cr. of the earlier year, (FY14).
Increment in deterioration from INR 67.81 Cr. in (FY14) to INR 105.52 Cr. in (FY15) brought about extra increment of INR 37.71 Cr. because of progress in Company's' demonstration 2013, bringing about Net Loss of INR 183.68 Cr. for the year, (FY15).
Be that as it may, Revenue for the quarter finished, (Q4 FY15) remained at INR 90.48 Cr. as against INR 78.16 Cr. of the past quarter (Q3 FY15), demonstrating a development of 15.76%
Complete Consolidated Revenue for the present year finished, (FY15) lessened to INR 2737.88 Cr. as against INR 3075.66 Cr. of the most recent year (FY14) with EBIDTA% insignificantly up from 8.35% to 8.44%.
"Disappointment will never surpass me if my definition to succeed is sufficiently solid" this expression of Dr. Kalam is maybe most able, when I consider India Business.
As you know, India Business in most recent two years in experiencing certain anxiety because of befuddle of money streams affecting crude material acquirement and meeting clients'' orders close by, subsequently our top and main concern has endured to a vast degree.
We have strived difficult to meet our leaser duty – with just about 60% determination of obligation through different choices and structures admissible under managing an account system. We are sure to pivot headwinds, through our ceaseless, aggregate, antagonistic try, investigating every single conceivable alternative.
With BRAG business hinting at obvious energy, close by India obligation under expedient determination, I am sure that your Company will soon turn out from avenue of its turbulent past to a superior and brilliant future in the coming monetary year.
As I close, might I, in the interest of your Board of Directors and the workers of your Company, at the end of the day thank you for your proceeded with backing and support.
Much thanks to you, Ladies and Gentlemen.
Mohan H. Bhandari
Administrator and Managing Director
